International Journal of Medical and Pharmaceutical Research
2023, Volume-4, Issue-2 doi: 10.5281/zenodo.7823590
Original Article
Characterization and Antibiotic Susceptibility Testing Of Acinetobacter Species in a Tertiary Care Hospital with Special Reference to NDM and OXA Genes
 ,
 ,
Published
April 13, 2023
Abstract
Background-Acinetobacter has emerged as a nosocomial pathogen. It was sensitive to most antibiotics, but today it exhibits resistance to most first line antibiotics. Carbapenems are the drug of choice for treating this infection but now resistance to carbapenems is being reported worldwide. Antibiotic susceptibility pattern of Acinetobacter may vary geographically and between various units of the same hospital at various point of time. The variation in antibiogram necessitates a periodic surveillance. Hence this study was conducted to understand the difference in phenotypic and genotypic methods by detection of OXA and NDM genes for accurate identification of antibiotic resistance, thus enabling successful implementation of antibiotic policy. METHODS- 70 isolates of Acinetobacter were collected and speciated. Antibiotic susceptibility pattern of all the isolates was determined and the carbapenem resistant isolates were subjected to real-time PCR for identification of NDM and OXA genes. RESULTS- A baumannii was the most common (74.3%) species, followed by A. lwoffii (25.7%). A. lwoffii was 100% sensitive to carbapenems. 50 strains of A. baumannii were carbapenems resistant and remaining were susceptible. In Carbapenem resistant A baumannii OXA 23 and OXA 51 are the most common gene detected by realtime PCR, followed by OXA 48 and OXA 58, while NDM was detected in 100% strains. DISCUSSION AND CONCLUSION- Knowledge of NDM and OXA producing Acinetobacter is imperative in formulating Institutional antibiotic stewardship program and infection control practices to control the spread of carbapenem resistant strains of Acinetobacterbaumanii. This information is extremely valuable for pharmaceutical companies towards development of newer antibiotics.
Recommended Articles
Loading Image...
Volume-4, Issue-2
Citations
2584 Views
234 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved